Human Molecular Genetics Advance Access originally published online on March 30, 2007
Human Molecular Genetics 2007 16(9):1098-1112; doi:10.1093/hmg/ddm059
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth
Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
* To whom correspondence should be addressed at: Department of Neurology, Washington University School of Medicine, PO Box 8111, 660 S. Euclid Avenue, St Louis, MO 63110, USA. Tel: +1 3143627379; Fax: +1 3143622388; Email: gutmannd{at}wustl.edu
Received December 22, 2006; Accepted March 13, 2007
The tumor microenvironment is considered to play an important role in tumor formation and progression by providing both negative and positive signals that influence tumor cell growth. We and others have previously shown that brain tumor (glioma) formation in Nf1 genetically engineered mice requires a microenvironment composed of cells heterozygous for a targeted Nf1 mutation. Using NF1 as a model system to understand the contribution of the tumor microenvironment to glioma formation, we show that Nf1+/– brain microglia produce specific factors that promote Nf1–/– astrocyte growth in vitro and in vivo and identify hyaluronidase as one of these factors in both genetically engineered Nf1 mouse and human NF1-associated optic glioma. We further demonstrate that blocking hyaluronidase ameliorates the ability of Nf1+/– microglia to increase Nf1–/– astrocyte proliferation and that hyaluronidase increases Nf1–/– astrocyte proliferation in an MAPK-dependent fashion. Lastly, inhibiting microglia activation in genetically engineered Nf1 mice significantly reduces mouse optic glioma proliferation in vivo. Collectively, these studies identify Nf1+/– microglia as an important stromal cell type that promotes Nf1–/– astrocyte and optic glioma growth relevant to the pathogenesis of NF1-associated brain tumors and suggest that future brain therapies might be directed against paracrine factors produced by cells in the tumor microenvironment.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Lin, J. Chen, J. A. Richardson, and L. F. Parada Mice lacking neurofibromin develop gastric hyperplasia Am J Physiol Gastrointest Liver Physiol, October 1, 2009; 297(4): G751 - G761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Daginakatte, S. M. Gianino, N. W. Zhao, A. S. Parsadanian, and D. H. Gutmann Increased c-Jun-NH2-Kinase Signaling in Neurofibromatosis-1 Heterozygous Microglia Drives Microglia Activation and Promotes Optic Glioma Proliferation Cancer Res., December 15, 2008; 68(24): 10358 - 10366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Gutmann Using Neurofibromatosis-1 to Better Understand and Treat Pediatric Low-Grade Glioma J Child Neurol, October 1, 2008; 23(10): 1186 - 1194. [Abstract] [PDF]
|
|
|
|
|
|
K. M. Reilly, J. B. Rubin, R. J. Gilbertson, J. R. Garbow, M. F. Roussel, and D. H. Gutmann Rethinking Brain Tumors: The Fourth Mouse Models of Human Cancers Consortium Nervous System Tumors Workshop Cancer Res., July 15, 2008; 68(14): 5508 - 5511. [Full Text] [PDF]
|
|
|
|
|
|
B. Hegedus, D. Banerjee, T.-H. Yeh, S. Rothermich, A. Perry, J. B. Rubin, J. R. Garbow, and D. H. Gutmann Preclinical Cancer Therapy in a Mouse Model of Neurofibromatosis-1 Optic Glioma Cancer Res., March 1, 2008; 68(5): 1520 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Warrington, B. M. Woerner, G. C. Daginakatte, B. Dasgupta, A. Perry, D. H. Gutmann, and J. B. Rubin Spatiotemporal Differences in CXCL12 Expression and Cyclic AMP Underlie the Unique Pattern of Optic Glioma Growth in Neurofibromatosis Type 1 Cancer Res., September 15, 2007; 67(18): 8588 - 8595. [Abstract] [Full Text] [PDF]
|
|